Study Phase 3

A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg Per Day

Trial Information

Generic NameMethylphenidate HClProduct NameCONCERTA®Therapeutic AreaBehaviors and Mental DisordersEnrollment284% Female51%% White100%
Product ClassStimulants/ADHD/AnorexiantsSponsor Protocol NumberJNS001-JPN-A01Data PartnerJohnson & JohnsonCondition StudiedAttention Deficit Hyperactivity DisorderMean/Median Age (Years)33.5

Supporting Documentation

  • Collected Datasets Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.